Keros Therapeutics, Inc. (KROS) Balance Sheet
As of 2026-06-30 (10-Q), Keros Therapeutics, Inc. (KROS) reported total assets of $287.6M, total liabilities of $25.3M and shareholders' equity of $262.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $257.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KROSKeros Therapeutics, Inc.Follow KROS — free
—
Price chart with a free account
- Market cap
- 223.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 265.9 | 230.0 | 279.0 | 331.1 | 559.9 | 287.4 | 257.6 | |
| Receivables | 0.0 | 18.0 | 0.0 | 0.1 | 2.7 | 3.6 | 0.0 | |
| Current assets | 267.7 | 251.4 | 285.8 | 347.3 | 588.9 | 315.4 | 266.9 | |
| Total assets | 269.4 | 255.3 | 306.8 | 370.0 | 615.9 | 338.0 | 287.6 | |
| Current liabilities | 7.2 | 11.8 | 16.5 | 24.4 | 27.5 | 20.4 | 12.2 | |
| Total liabilities | 7.7 | 12.1 | 29.4 | 37.8 | 44.3 | 34.9 | 25.3 | |
| Shareholders' equity | 261.7 | 243.2 | 277.4 | 332.2 | 571.6 | 303.1 | 262.3 |
USD millions · SEC XBRL
Keros Therapeutics, Inc. — questions
- How much cash does Keros Therapeutics, Inc. have?
- $257.6M in cash and cash equivalents as of 2026-06-30.
- What are Keros Therapeutics, Inc.'s total assets?
- $287.6M as of 2026-06-30.
- What is Keros Therapeutics, Inc.'s shareholders' equity?
- $262.3M as of 2026-06-30.
Every figure on this page comes from Keros Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.